Drugmakers Seek Supreme Court Intervention to Restore Abortion Pill Access by Mail

Mifepristone manufacturers Danco Laboratories and GenBioPro filed an emergency appeal to the US Supreme Court on Saturday, May 2, 2026, asking the justices to block a lower-court ruling that requires patients to obtain the abortion pill through an in-person medical exam — a decision the companies warn will create 'tremendous uncertainty' and shut off mail-order access used in nearly two-thirds of pregnancy terminations nationwide.

The Details

The appeal challenges a decision by the US Court of Appeals for the 5th Circuit that temporarily reinstated an in-person prescription requirement for mifepristone, according to The Guardian. The ruling came in response to a legal challenge from Louisiana, which argues that mail delivery of the drug ignores complication risks such as sepsis and hemorrhaging and allows patients to bypass state-level abortion bans. The 5th Circuit found that allowing mifepristone by mail 'facilitates nearly 1,000 illegal abortions in Louisiana per month,' The Guardian reported.

Danco Laboratories said in its emergency filing that 'Louisiana's complaint should have been dismissed outright,' according to The Guardian. The company argued that the lower court's ruling 'injects immediate confusion and upheaval into highly time-sensitive medical decisions,' The Guardian reported. Danco also warned that 'tremendous uncertainty will surround the legal status of mifepristone throughout the country' if the in-person requirement stands, Politico reported.

The New York Times reported that the manufacturers are asking the Supreme Court to intervene quickly because the 5th Circuit's decision disrupts a distribution system that has operated under FDA rules allowing telehealth prescribing and mail delivery. The case adds to a growing stack of abortion-related litigation before the court since the 2022 reversal of Roe v. Wade.

Context

Mifepristone is used in nearly two-thirds of pregnancy terminations in the United States, according to The Guardian. The FDA is currently reviewing the safety of the drug following requests from nearly two dozen Republican state attorneys general. Abortion opponents have targeted mail-order access in multiple states since the Supreme Court eliminated the federal constitutional right to abortion in Dobbs v. Jackson Women's Health Organization, but federal courts have issued conflicting rulings on whether states can override FDA approval of the medication.

What's Next

The Supreme Court has not yet indicated whether it will grant the emergency stay or schedule oral arguments. If the justices decline to intervene, the 5th Circuit's in-person requirement could remain in effect while the underlying case proceeds. Meanwhile, the FDA's ongoing safety review could produce revised labeling or distribution rules that further reshape how the drug reaches patients.